Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Declines By 22.1%

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the target of a significant drop in short interest in February. As of February 13th, there was short interest totaling 7,474,168 shares, a drop of 22.1% from the January 29th total of 9,597,134 shares. Approximately 10.9% of the company’s stock are short sold. Based on an average daily volume of 2,061,707 shares, the short-interest ratio is presently 3.6 days. Based on an average daily volume of 2,061,707 shares, the short-interest ratio is presently 3.6 days. Approximately 10.9% of the company’s stock are short sold.

Analysts Set New Price Targets

MIST has been the subject of a number of research reports. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Zacks Research downgraded shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Wells Fargo & Company increased their price objective on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, Wall Street Zen cut shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.00.

Insider Transactions at Milestone Pharmaceuticals

In other Milestone Pharmaceuticals news, insider Lorenz Muller sold 53,566 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $2.32, for a total transaction of $124,273.12. Following the sale, the insider owned 196,486 shares in the company, valued at $455,847.52. This represents a 21.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Joseph Oliveto sold 34,523 shares of the stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $1.93, for a total value of $66,629.39. Following the transaction, the chief executive officer directly owned 482,744 shares in the company, valued at approximately $931,695.92. This represents a 6.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 416,327 shares of company stock valued at $935,458 in the last three months. Corporate insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Creative Planning boosted its position in shares of Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after buying an additional 10,000 shares during the period. Raymond James Financial Inc. raised its stake in Milestone Pharmaceuticals by 30.1% during the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after acquiring an additional 10,000 shares in the last quarter. Bay Rivers Group boosted its position in Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after acquiring an additional 12,170 shares during the period. Sapient Capital LLC bought a new position in shares of Milestone Pharmaceuticals in the third quarter worth $25,000. Finally, Strategic Family Wealth Counselors L.L.C. acquired a new position in Milestone Pharmaceuticals during the 4th quarter valued at about $25,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

Milestone Pharmaceuticals Stock Performance

Shares of MIST opened at $1.71 on Monday. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $3.06. The company has a market cap of $145.64 million, a price-to-earnings ratio of -2.09 and a beta of 0.48. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. The firm has a fifty day moving average of $1.91 and a 200-day moving average of $2.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.